Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.54 USD | -6.03% | +0.15% | +11.22% |
Feb. 27 | North American Morning Briefing : Stock Futures -2- | DJ |
Feb. 26 | Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating | MT |
Business Summary
Number of employees: 164
Managers
Managers | Title | Age | Since |
---|---|---|---|
Andrew Robbins
CEO | Chief Executive Officer | 48 | 20-10-22 |
John Green
DFI | Director of Finance/CFO | 43 | 18-05-31 |
Rachael Easton
CTO | Chief Tech/Sci/R&D Officer | - | 22-11-27 |
Brad Barnett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jessica Sachs
CTO | Chief Tech/Sci/R&D Officer | 49 | 17-03-31 |
John Robinson
CTO | Chief Tech/Sci/R&D Officer | 50 | 21-04-05 |
Christi Waarich
IRC | Investor Relations Contact | - | - |
Dana Martin
PRN | Corporate Officer/Principal | - | 21-10-31 |
Sara Saltzman
LAW | General Counsel | - | 18-12-31 |
Human Resources Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 19-07-25 |
Matthew Ros
BRD | Director/Board Member | 57 | 19-07-25 |
Todd Shegog
BRD | Director/Board Member | 59 | 21-02-21 |
Karen Ferrante
BRD | Director/Board Member | 66 | 18-01-31 |
Andrew Robbins
CEO | Chief Executive Officer | 48 | 20-10-22 |
Peter Harwin
CHM | Chairman | 38 | 20-07-05 |
Chris Cain
BRD | Director/Board Member | 40 | 20-07-05 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 95,613,396 | 94,354,142 ( 98.68 %) | 0 | 98.68 % |
Stock B | 0 | 74,465 | 0 | 0 |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.22% | 625M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.75% | 22.2B | |
-16.53% | 21.23B | |
-9.12% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- COGT Stock
- Company Cogent Biosciences, Inc.